PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
20-Nov-2024 Lindus Health Rolls Out “All-in-One Infectious Disease CRO” Bespoke to Clinical Trials for Infectious Disease Interventions Lindus Health
19-Nov-2024 Modus Therapeutics Receives Approval to Initiate a Phase IIa Clinical Trial for Chronic Kidney Disease (CKD) Modus Therapeutics
19-Nov-2024 Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001 Thermosome
14-Nov-2024 Coronado Research Limited announce the appointment of Alexander McCormick as Chief Commercial Officer Coronado Research
13-Nov-2024 Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients Microbiotica
13-Nov-2024 Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist Nxera Pharma
12-Nov-2024 Gifthealth Announces Strategic Partnership with United Digestive Gifthealth
12-Nov-2024 French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance AdipoPharma
11-Nov-2024 AstraZeneca and Amgen’s Tezspire meets both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps AstraZeneca
11-Nov-2024 Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board Ebenbuild
05-Nov-2024 Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer Nouscom
04-Nov-2024 Ondine Biomedical's US $11m fundraise enables a Q4 2024 start of its pivotal Phase 3 US trial Ondine Biomedical
04-Nov-2024 Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data Tiziana Life Sciences
29-Oct-2024 Alira Health Releases Global Report on Trends and Competitive Dynamics in the Biosimilar Market Alira Health
29-Oct-2024 TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease JOHNSON & JOHNSON
28-Oct-2024 Almirall´s 2024 Immunoskin conference hosts leading experts in inflammatory skin conditions to advance science and treatment options Almirall
28-Oct-2024 Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis AstraZeneca
28-Oct-2024 Innovative Trials named a top UK women-powered company in clinical research Innovative Trials
28-Oct-2024 Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025 Ottimo Pharma
28-Oct-2024 Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance Sanofi